Proliferation-independent control of tumor glycolysis by PDGFR-mediated AKT activation

Cancer Research

Volumn 73, Issue 6, 2013, Pages 1831-1843

  Ran, Cong ^a,b   Liu, Huan ^a,b   Hitoshi, Yasuyuki ^a,c   Israel, Mark A ^a,b  

^a NORRIS COTTON CANCER CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c Department of Neurosurgery Rosai Hospital ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER REGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME ACTIVATION; GENE AMPLIFICATION; GLIOMA; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOIMMUNOPRECIPITATION; RTK SIGNALING PATHWAY; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL PROLIFERATION; ENZYME ACTIVATION; GLIOMA; GLYCOLYSIS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MODELS, ANIMAL; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84875459340     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2460     Document Type: Article

References (49)

1. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008;134:703-7.
2. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008;13:472-82.
3. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 2009;23:537-48.
4. Israel M, Schwartz L. The metabolic advantage of tumor cells. Mol Cancer 2011;10:70.
5. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
6. Hayat MA. Methods of cancer diagnosis, therapy, and prognosis. 1st ed. Union, NJ: Springer; 2010.
7. Wolf A, Agnihotri S, Guha A. Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget 2011;1:552-62.
8. Thong FSL, Bilan PJ, Klip A. The Rab GTPase-activating protein AS160 integrates Akt, protein kinase C, and AMP-activated protein kinase signals regulating GLUT4 traffic. Diabetes 2007;56: 414-23.
9. Whiteman EL, Cho H, Birnbaum MJ. Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab 2002;13: 444-51.
10. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25.
11. Weihua Z, Tsan R, Huang WC,WuQ, Chiu CH, Fidler IJ, et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008;13:385-93.
12. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci signal 2009;2:ra73.
13. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001;15:1913-25.
14. Hambardzumyan D, Squatrito M, Carbajal E, Holland EC. Glioma formation, cancer stem cells, and akt signaling. Stem Cell Rev 2008;4: 203-10.
15. Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, Holland EC. Dosedependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 2004;64:4783-9.
16. TCGA. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455: 1061-8.
17. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-44.
18. Hitoshi Y, Harris BT, Liu H, Popko B, Israel MA. Spinal glioma: plateletderived growth factor B-mediated oncogenesis in the spinal cord. Cancer Res 2008;68:8507-15.
19. Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ. Imatinib (STI571)-mediated changes in glucose metabolismin human leukemia BCR-ABL-positive cells. Clin Cancer Res 2004;10:6661-8.
20. Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 2000;275:8027-31.
21. O'Neil RG, Wu L, Mullani N. Uptake of a fluorescent deoxyglucose analog (2-NBDG) in tumor cells. Mol Imaging Biol 2005;7:388-92.
22. Elstrome RL, Bauer DE, Buzzai MKR, Karnauskas R, Harris MH, Plas DR, et al. Akt Stimulates Glycolysis in Cancer Cells. Cancer Res 2004;64:3892-99.
23. Wlodkowic D, Skommer J, Darzynkiewicz Z. Flow cytometry-based apoptosis detection. Methods Mol Biol 2009;559:19-32.
24. Fishbein I, Waltenberger J, Banai S, Rabinovich L, Chorny M, Levitzki A, et al. Local delivery of platelet-derived growth factor receptorspecific tyrphostin inhibits neointimal formation in rats. Arterioscler Thromb Vasc Biol 2000;20:667-76.
25. Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T, et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1995;182:367-77.
26. Hoehn KL, Hohnen-Behrens C, Cederberg A, Wu LE, Turner N, Yuasa T, et al. IRS1-independent defects define major nodes of insulin resistance. Cell Metab 2008;7:421-33.
27. Perez J, Hill BG, Benavides GA, Dranka BP, Darley-Usmar VM. Role of cellular bioenergetics in smooth muscle cell proliferation induced by platelet-derived growth factor. Biochem J 2010;428: 255-67.
28. Umahara M, Okada S, Yamada E, Saito T, Ohshima K, Hashimoto K, et al. Tyrosine phosphorylation of Munc18c regulates platelet-derived growth factor-stimulated glucose transporter 4 translocation in 3T3L1 adipocytes. Endocrinology 2008;149:40-9.
29. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 2011;208: 313-26.
30. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A 2009;106:12932-7.
31. Ko YH, Pan W, Inoue C, Pedersen PL. Signal transduction to mitochondrial ATP synthase: Evidence that PDGF-dependent phosphorylation of the delta-subunit occurs in several cell lines, involves tyrosine, and is modulated by LPA. Mitochondrion 2002; 1:339-48.
32. Kang SG, Chung H, Yoo YD, Lee JG, Choi YI, Yu YS. Mechanism of growth inhibitory effect of Mitomycin-C on cultured human retinal pigment epithelial cells: apoptosis and cell cycle arrest. Curr Eye Res 2001;22:174-81.
33. Liu K-W, Feng H, Bachoo R, Kazlauskas A, Smith EM, Symes K, et al. SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans. J Clin Invest 2011;121: 905-17.
34. Grassian AR, Metallo CM, Coloff JL, Stephanopoulos G, Brugge JS. Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Genes Dev 2011;25:1716-33.
35. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1999;96:2110-5.
36. Yecies Jessica, Zhang HuiH, Menon S, Liu S, Yecies D, Lipovsky AI, et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metabolism 2011;14:21-32.
37. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
38. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
39. Goidts V, Bageritz J, Puccio L, Nakata S, Zapatka M, Barbus S, et al. RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. Oncogene 2012;31: 3235-43.
40. Hitosugi T, Fan J, Chung TW, Lythgoe K, Wang X, Xie J, et al. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell 2011;44:864-77.
41. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008;452:230-3.
42. Lemons JMS, Feng X-J, Bennett BD, Legesse-Miller A, Johnson EL, Raitman I, et al. Quiescent fibroblasts exhibit high metabolic activity. PLoS Biol 2010;8:e1000514.
43. Funes JM, Quintero M, Henderson S, Martinez D, Qureshi U, Westwood C, et al. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci U S A 2007; 104:6223-8.
44. Weinberg F, Hamanaka R, WheatonWW,Weinberg S, Joseph J, Lopez M, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 2010;107: 8788-93.
45. Livnat T, Chen-Zion M, Beitner R. Platelet-derived growth factor (PDGF) rapidly stimulates binding of glycolytic enzymes to muscle cytoskeleton, prevented by calmodulin antagonists. Biochem Med Metab Biol 1994;53:28-33.
46. Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, et al. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res 2009;15:6258-66.
47. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Molecular Cell 2010;40:310-22.
48. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9.
49. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012;21: 297-308.